Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Novartis Ag (NVSEF) EBIAT (2016 - 2025)

Historic EBIAT for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to $2.4 billion.

  • Novartis Ag's EBIAT fell 1475.18% to $2.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $14.0 billion, marking a year-over-year increase of 1698.63%. This contributed to the annual value of $14.0 billion for FY2025, which is 1698.63% up from last year.
  • Per Novartis Ag's latest filing, its EBIAT stood at $2.4 billion for Q4 2025, which was down 1475.18% from $3.9 billion recorded in Q3 2025.
  • Novartis Ag's 5-year EBIAT high stood at $16.3 billion for Q4 2021, and its period low was $1.3 billion during Q4 2022.
  • Over the past 5 years, Novartis Ag's median EBIAT value was $2.7 billion (recorded in 2021), while the average stood at $3.4 billion.
  • Per our database at Business Quant, Novartis Ag's EBIAT soared by 67684.61% in 2021 and then crashed by 9193.55% in 2022.
  • Novartis Ag's EBIAT (Quarter) stood at $16.3 billion in 2021, then plummeted by 91.94% to $1.3 billion in 2022, then soared by 236.2% to $4.4 billion in 2023, then tumbled by 36.21% to $2.8 billion in 2024, then dropped by 14.75% to $2.4 billion in 2025.
  • Its EBIAT was $2.4 billion in Q4 2025, compared to $3.9 billion in Q3 2025 and $4.0 billion in Q2 2025.